# US 2021/0260125 A1 · Anti-slamf7 chimeric antigen receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260125 A1
- Document ID: US20210260125A1
- Status: Published application
- Kind: A1
- Application number: 17/255,005
- Filed: 2019-06-26
- Published: 2021-08-26
- Earliest claimed: 2018-07-03
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services
- Inventors: James N. Kochenderfer; Steven A. Feldman
- Web page: https://patentgrep.com/patent/US20210260125A1

## CPC

- C07K 14/70517: {CD8}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/4211: {CD19 or B4}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- A61K 2239/28: Expressing multiple CARs, TCRs or antigens
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.

## Claims

### Claim 1

A nucleic acid comprising:
(a) a suicide gene; and
(b) a nucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen recognition domain, a transmembrane (TM) domain, and a T cell activation domain, and wherein the CAR has antigenic specificity for signaling lymphocyte activating molecule F7 (SLAMF7).

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein the antigen recognition domain comprises the amino acid sequences of:
(a) SEQ ID NOs: 1-6 or
(b) SEQ ID NOs: 7-12.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein the antigen recognition domain comprises the amino acid sequences of:
(a) SEQ ID NOs: 13-14 or
(b) SEQ ID NOs: 15-16.

### Claim 4 (depends on 1)

The nucleic acid of claim 1, wherein the T-cell activation domain comprises a T-cell signaling domain of any one of the following proteins: a human CD28 protein, a human CD3-zeta protein, a human FcRγ protein, a CD27 protein, an OX40 protein, a human 4-1BB protein, a human inducible T-cell costimulatory protein (ICOS), modified versions of any of the foregoing, or any combination of the foregoing.

### Claim 5 (depends on 1)

The nucleic acid of claim 1, wherein the TM domain comprises a TM domain of CD8a or CD28.

### Claim 6 (depends on 1)

The nucleic acid of claim 1, wherein the suicide gene is the inducible caspase 9 (IC9) gene.

### Claim 7 (depends on 1)

The nucleic acid of claim 1, further comprising a nucleotide sequence encoding a cleavable linker sequence.

### Claim 8 (depends on 7)

The nucleic acid of claim 7, wherein the nucleotide sequence encoding the cleavable linker sequence is positioned between the nucleotide sequence encoding the CAR and the suicide gene.

### Claim 9 (depends on 1)

The nucleic acid of claim 1, wherein the nucleotide sequence encoding the CAR is positioned 5′ of the suicide gene.

### Claim 10 (depends on 1)

The nucleic acid of claim 1, wherein the nucleotide sequence encoding the CAR is positioned 3′ of the suicide gene.

### Claim 11 (depends on 1)

The nucleic acid of claim 1, wherein the nucleotide sequence encodes the amino acid sequence of any one of SEQ ID NOs: 27-31.

### Claim 12 (depends on 1)

Protein(s) encoded by the nucleic acid of claim 1.

### Claim 13

A CAR comprising an antigen recognition domain, a TM domain, and a T cell activation domain, wherein the CAR has antigenic specificity for SLAMF7, wherein the CAR does not comprise any of a Myc tag, an IgG4-Fc spacer, or an IgG4-Fc spacer which has been modified to prevent binding of an Fc receptor.

### Claim 14 (depends on 13)

The CAR of claim 13, wherein the antigen recognition domain comprises the amino acid sequences of:
(a) SEQ ID NOs: 1-6 or
(b) SEQ ID NOs: 7-12.

### Claim 15 (depends on 13)

The CAR of claim 13, wherein the antigen recognition domain comprises the amino acid sequences of:
(a) SEQ ID NOs: 13-14 or
(b) SEQ ID NOs: 15-16.

### Claim 16 (depends on 13)

The CAR of claim 13, wherein the T-cell activation domain comprises a T-cell signaling domain of any one of the following proteins: a human CD28 protein, a human CD3-zeta protein, a human FcRγ protein, a CD27 protein, an OX40 protein, a human 4-1BB protein, a human inducible T-cell costimulatory protein (ICOS), modified versions of any of the foregoing, or any combination of the foregoing.

### Claim 17 (depends on 1)

The CAR of claim 1, wherein the TM domain comprises a TM domain of CD8a or CD28.

### Claim 18 (depends on 1)

The CAR of claim 1, comprising the amino acid sequence of any one of SEQ ID NOs: 27-31.

### Claim 19 (depends on 13)

A nucleic acid comprising a nucleotide sequence encoding the CAR of claim 13.

### Claim 20 (depends on 1)

A vector comprising the nucleic acid of claim 1.

### Claim 21 (depends on 20)

An isolated host cell comprising the vector of claim 20.

### Claim 22 (depends on 21)

The isolated host cell of claim 21, wherein the host cell is a T-cell.

### Claim 23 (depends on 21)

The isolated host cell of claim 21, wherein the host cell is a natural killer (NK) cell.

### Claim 24 (depends on 21)

A population of cells comprising at least one host cell of claim 21.

### Claim 25 (depends on 1)

A combination of first and second proteins encoded by the nucleotide sequence of the nucleic acid of claim 1, wherein:
(a) the first protein is encoded by the nucleotide sequence encoding the CAR; and
(b) the second protein is encoded by the suicide gene.

### Claim at position 26

26-27. (canceled)

### Claim 28 (depends on 1)

A method of treating or preventing cancer in a mammal, the method comprising administering to the mammal the nucleic acid of claim 1, in an amount effective to treat or prevent cancer in the mammal.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the cancer is multiple myeloma.
